3 New Strong Buy Ratings from Top-Rated Analysts: 11/13/2025
Here are three strong picks to consider adding to your watchlist, all sourced from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Why analysts believe Five9 (FIVN) could double in the coming year
- AbbVie (ABBV) has several near-term tailwinds worth watching
- The real reason why Insulet (PODD) has a competitive advantage
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
How to Become Your Own Bank (And Earn 30-400% Annually) A former Wall Street insider with a CFA Charter is showing crypto investors how to "become their own bank". This select group is using the same liquidity strategy BlackRock uses to dominate traditional markets... except in crypto where returns are exponentially higher. This allows them to generate income regardless of market direction. Regular investors are already earning up to triple-digit annual returns. Click here for the free training to learn how you can earn an extra 30-400% on your digital assets.1. Five9 (NASDAQ: FIVN)
Five9 provides cloud-based contact center software solutions, delivering virtual contact center platforms that enable companies to manage customer service operations efficiently. Despite recent stock pressure, the company posted strong Q3 results and maintains robust analyst support.
Zen Rating: B (Buy) — see full analysis
Recent Price: $20.33 — get current quote
Max 1-year forecast: $40.00
Why we're watching:
- Analyst support: FIVN has a Strong Buy consensus among the analysts we track, with 6 Strong Buy ratings and 2 Hold ratings. See the ratings
- For instance, Barclays researcher Raimo Lenschow (a top 2% rated analyst) recently maintained his Strong Buy rating with a $29 price target, implying 42.65% upside potential. This came on the heels of a double earnings beat.
- In addition, the company also just announced a share repurchase program for up to $150M of common stock, inclusive of a $50M accelerated share repurchase. Per the company CEO, this “demonstrates the conviction of our Board and management team in the strength of our business and long-term value creation opportunity.”
- Zen Ratings vets FIVN with an overall B (Buy) rating, putting the stock in a class of winners that have historically delivered 19.88% annual returns.
- The Component Grades show several areas of strength, including above-average B ratings for Value, Growth, and Artificial Intelligence (here’s how that rating works) — despite a D grade for Momentum, FIVN has several ingredients for near-term success. (See all 7 Component Grades here)
2. AbbVie Inc (NYSE: ABBV)
This pharma heavyweight boasts a strong pipeline and diversified portfolio — and continues to demonstrate resilience in navigating patent cliffs while driving growth through innovative therapies.
Zen Rating: B (Buy) — see full analysis
Recent Price: $225.17 — get current quote
Max 1-year forecast: $289.00
Why we're watching:
- Analyst support: The stock enjoys strong Wall Street backing with 8 Strong Buy ratings, 3 Buy ratings, and 2 Hold ratings among the analysts we track. See the ratings
- For example, Piper Sandler's David Amsellem (a top 6% rated analyst) recently maintained his Strong Buy rating with a $289 price target, indicating potential upside of 28.35% from current levels.
- The maintained rating came on the heels of the company’s earnings; Amsellem predicted that Skyrizi estimates will rise in 2026 and beyond, and that he expects that AbbVie's Neuroscience segment, mostly still unnoticed by the Street, will see higher estimates for key products.
- Industry ranking context: ABBV is currently the 7th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A, positioning it favorably among pharmaceutical peers.
- Zen Rating highlights: As a B-rated stock, ABBV ranks in the top 17% of the 4600+ tickers we track.
- Component Grades: With particularly strong marks in Safety (A) and Sentiment (B), the stock demonstrates excellent stability — and enjoys great optimism among Wall Street’s brightest minds. (See all 7 Zen Component Grades here)
3. Insulet (NASDAQ: PODD)
Insulet is best known for its Omnipod System, a tubeless insulin delivery device for people with insulin-dependent diabetes. The company recently delivered another strong beat-and-raise quarter, driven by record new patient starts and international outperformance.
Zen Rating: B (Buy) — see full analysis
Recent Price: $314.27 — get current quote
Max 1-year forecast: $428.00
Why we're watching:
- Analyst support: Wall Street is bullish on PODD with 6 Strong Buy and 4 Buy ratings among the analysts we track. See the ratings
- Canaccord Genuity researcher William Plovanic (a top 11% rated analyst) recently maintained his price target following Q3 results, characterizing them as "another strong beat-and-raise" driven by OUS outperformance and record new patient starts in both US Type 1 and Type 2 diabetes markets.
- The company recently delivered a double earnings beat, with management raising full-year 2025 guidance to 28-29% revenue growth.
- Zen Rating highlights: PODD ranks in the top 10% of the 4600+ stocks we track, with an overall Zen Rating of B (Buy).
- PODD’s Component Grade for Safety ranks in the top 15%, and Momentum ranks in the top 10%, reflecting strong technical performance alongside solid operational fundamentals. (See all 7 Zen Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.